Supplemental Information

Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July-August 2020: a mail-based cross-sectional study

* Correspondence to: <u>alover@umass.edu</u>

School of Public Health and Health Sciences University of Massachusetts- Amherst 715 North Pleasant Street Amherst, MA 01003-9304 phone: 413-545-7426

Supplemental Information

<u>Supplemental Table 1</u>: <u>Comparison of characteristics of participants selected for randomization and those not selected for randomization, SARS-CoV-2 serosurvey, Massachusetts, USA, Jul-Aug 2020.</u>

	Primary Sampling Group (undergraduates)		Secondary sampling group (employees)	
	Randomized	Randomized	Not Randomized	Randomized
n	869	752	2253	249
Age (mean (SD))	20.64 (3.09)	20.18 (1.79)	42.05 (13.53)	40.69 (13.88)
Gender (%)				
Unknown	0 (0.0)	0 (0.0)	1 (0.0)	0 (0.0)
Female	525 (60.4)	453 (60.2)	1262 (56.0)	147 (59.0)
Gender diverse	12 (1.4)	8 (1.1)	49 (2.2)	3 (1.2)
Male	332 (38.2)	291 (38.7)	941 (41.8)	99 (39.8)
Self-reported febrile illness since February (%)				
Unknown	1 (0.1)	2 (0.3)	6 (0.3)	0 (0.0)
No	568 (65.4)	499 (66.4)	1658 (73.6)	189 (75.9)
Not sure	75 (8.6)	57 (7.6)	154 (6.8)	16 (6.4)
Yes	225 (25.9)	194 (25.8)	435 (19.3)	44 (17.7)
Education (%)				
Unknown	4 (0.5)	3 (0.4)	6 (0.3)	1 (0.4)
BA/BS	15 (1.7)	14 (1.9)	509 (22.6)	64 (25.7)
High school / GED	90 (10.4)	108 (14.4)	46 (2.0)	2 (0.8)
More than BA/BS	2 (0.2)	0 (0.0)	1528 (67.8)	166 (66.7)
Prefer not to answer Some college	1 (0.1) 757 (87.1)	0 (0.0) 627 (83.4)	13 (0.6) 151 (6.7)	1 (0.4) 15 (6.0)
Response to, "I am afraid of COVID-19" (%)	, ,	,	,	, ,
Unknown	1 (0.1)	2 (0.3)	2 (0.1)	0 (0.0)
Neither agree nor disagree	199 (22.9)	141 (18.8)	399 (17.7)	51 (20.5)
Somewhat agree	390 (44.9)	374 (49.7)	1051 (46.6)	100 (40.2)
Somewhat disagree	115 (13.2)	99 (13.2)	153 (6.8)	22 (8.8)
Strongly agree	121 (13.9)	104 (13.8)	573 (25.4)	66 (26.5)
Strongly disagree	43 (4.9)	32 (4.3)	75 (3.3)	10 (4.0)

<u>Supplemental Table 2: Comparison of estimated seropositivity by sampling groups using alternative cutpoints for seropositivity, SARS-CoV-2 serosurvey, Massachusetts, USA, Jul-Aug 2020.</u>

Sampling Group	Cutoff Value	Unadjusted Prevalence (%)	Adjusted Prevalence (%) (95% confidence interval)
Primary sampling group (undergraduates)			
	2.49	4.6	5.3 (3.5 – 8.0)
	2.0	10.9	11.6 (9.1 – 15.0)
	2.1	8.7	9.2 (6.9 – 12.3)
	2.2	7.1	7.6 (5.5 – 10.6)
	2.3	5.9	6.5(4.5-9.3)
	2.4	5.0	5.6 (3.8 – 8.4)
	2.5	4.5	5.1 (3.3 – 7.9)
	2.6	4.0	4.5 (2.8 – 7.1)
	2.7	3.7	4.3 (2.6 – 6.9)
	2.8	3.3	3.9(2.3-6.5)
	2.9	2.8	3.5(2.0-6.2)
	3.0	2.4	3.3 (1.8 – 5.9)
Secondary sampling group (employees)			
	2.49	3.4	4.0 (2.2 – 7.4)
	2.0	7.5	8.2 (5.3 – 12.7)
	2.1	5.5	6.0(3.7-9.8)
	2.2	4.8	5.4 (3.2 – 9.2)
	2.3	4.8	5.4 (3.2 – 9.2)
	2.4	3.8	4.5(2.5-8.0)
	2.5	3.4	4.0 (2.2 – 7.4)
	2.6	2.4	3.0 (1.5 – 6.2)
	2.7	2.1	2.6(1.2-5.7)
	2.8	2.1	2.6(1.2-5.7)
	2.9	1.4	1.7 (0.7 – 4.6)
	3.0	1.0	1.3 (0.4 – 4.0)

<u>Supplemental Figure 1. Distributions of IgG lognormal optical density (OD) ratios, by subgroups, SARS-CoV-2, Massachusetts, USA, Jul-Aug 2020.</u>

